An HPLC-MS/MS method for quantitation of trelagliptin and application in a comparative pharmacokinetic study

被引:2
作者
Han, Ying [1 ]
Chen, Liqing [1 ]
Liu, Wei [1 ]
Xin, Xin [1 ]
Meng, Lingwei [1 ]
Chu, Xiaoyang [2 ]
Huang, Wei [1 ]
Jin, Mingji [1 ]
Gao, Zhonggao [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China
[2] 307 Hosp PLA, Beijing Inst Pharmacol & Toxicol, Dept Pharmaceut, 27 Taiping Rd, Beijing 100850, Peoples R China
关键词
comparative pharmacokinetics; HPLC-MS/MS; trelagliptin; Type 2 diabetes mellitus; RAT PLASMA; TYPE-2; INHIBITORS; ASSAY; ACID;
D O I
10.4155/bio-2018-0238
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Aim: A sensitive HPLC-MS/MS approach was established to quantify trelagliptin and explore the pharmacokinetic characteristics in rats for up to 7 days. Meanwhile, the pharmacokinetic differences of trelagliptin were investigated for the first time. Results/methodology: The ion pairs of m/z 358.2 -> 341.2 for trelagliptin and m/z 340.3 -> 116.1 for alogliptin (internal standard) were detected in positive mode. Trelagliptin displayed a good linearity in the range of 4-4000 ng/ ml (r(2) = 0.9997) with a mean recovery rate of 86.9-94.1%. Discussion/conclusion: Compared with normal groups, the T1/2, apparent volume of distribution, area under the curve and bioavailability in model rats were significantly increased while the apparent plasma clearance decreased. The approach is proved to be straightforward and appropriate for quantitation of trelagliptin and application in pharmacokinetics studies.
引用
收藏
页码:1755 / 1765
页数:11
相关论文
共 26 条
  • [1] An update on DPP-4 inhibitors in the management of type 2 diabetes
    Cahn, Avivit
    Cernea, Simona
    Raz, Itamar
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (04) : 409 - 419
  • [2] Pharmacokinetics of salsalate and salicylic acid in normal and diabetic rats
    Cao, Yanguang
    DuBois, Debra C.
    Almon, Richard R.
    Jusko, William J.
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2012, 33 (06) : 285 - 291
  • [3] DPP-4 inhibitors: pharmacological differences and their clinical implications
    Ceriello, Antonio
    Sportiello, Liberata
    Rafaniello, Concetta
    Rossi, Francesco
    [J]. EXPERT OPINION ON DRUG SAFETY, 2014, 13 : S57 - S68
  • [4] CFDA, GUID PRINC NONCL PHA
  • [5] Danafar H, 2015, PHARM SCI S1, V21, P167, DOI [10.15171/PS.2015.32, DOI 10.15171/PS.2015.32]
  • [6] Danafar H, 2015, ADV PHARM BULL, V5, P563, DOI 10.15171/apb.2015.076
  • [7] A Rapid and Sensitive LC-MS Method for Determination of Ezetimibe Concentration in Human Plasma: Application to a Bioequivalence Study
    Danafar, Hossein
    Hamidi, Mehrdad
    [J]. CHROMATOGRAPHIA, 2013, 76 (23-24) : 1667 - 1675
  • [8] Comparative pharmacokinetics of baicalin in normal and the type 2 diabetic rats after oral administration of the Radix scutellariae extract
    Deng, Yuan-Xiong
    Shi, Qun-Zhi
    Chen, Bo
    Zhang, Xiao-Jie
    Liu, Sheng-Zi
    Qiu, Xi-Min
    [J]. FITOTERAPIA, 2012, 83 (08) : 1435 - 1442
  • [9] A validated ultra-performance liquid chromatography-tandem mass spectrometry method to identify the pharmacokinetics of SR8278 in normal and streptozotocin-induced diabetic rats
    Dong, Dong
    Sun, Hua
    Wu, Zhufeng
    Wu, Baojian
    Xue, Yunxia
    Li, Zhijie
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2016, 1020 : 142 - 147
  • [10] The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    Drucker, Daniel J.
    Nauck, Michael A.
    [J]. LANCET, 2006, 368 (9548) : 1696 - 1705